Published in Cancer on June 01, 2007
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol (2013) 4.24
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol (2010) 2.49
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol (2014) 1.65
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol (2010) 1.39
Prognostic factors in renal cell carcinoma. World J Urol (2010) 1.34
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol (2011) 1.24
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer (2011) 1.15
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res (2009) 1.13
mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.12
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med (2010) 1.12
Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol (2011) 1.11
Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci U S A (2009) 1.10
mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol Med (2010) 1.10
Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer (2008) 1.06
Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res (2008) 1.03
Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol (2013) 1.02
FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res (2014) 1.02
Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer (2010) 1.01
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol (2008) 1.01
t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol (2014) 0.99
Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev (2013) 0.98
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Cancer Biol Ther (2009) 0.95
Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol (2008) 0.93
Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer (2014) 0.93
Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers. Oncol Lett (2011) 0.92
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res (2013) 0.91
Targeted therapy for renal cell carcinoma: The next lap. J Carcinog (2014) 0.89
Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther (2013) 0.89
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark (2009) 0.89
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol (2014) 0.88
EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch (2012) 0.88
Therapeutic evaluation of microRNAs by molecular imaging. Theranostics (2013) 0.88
Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study. Korean J Urol (2011) 0.87
Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells. Oncol Lett (2013) 0.85
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer (2013) 0.85
Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med (2012) 0.85
In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458. Cancer Cell Int (2014) 0.84
RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res (2014) 0.84
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics (2010) 0.83
Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch (2012) 0.83
Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer (2012) 0.83
Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism. Neoplasia (2014) 0.82
Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer. Oncol Lett (2011) 0.82
Acquired cystic disease-associated renal cell carcinoma: further characterization of the morphologic and immunopathologic features. Med Mol Morphol (2013) 0.82
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol (2012) 0.81
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci (2011) 0.81
Kidney cancer pathology in the new context of targeted therapy. Pathobiology (2011) 0.81
Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio (2014) 0.81
Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med (2014) 0.81
Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Hum Pathol (2012) 0.80
Multiple roles and therapeutic implications of Akt signaling in cancer. Onco Targets Ther (2009) 0.80
Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo. Cancer Prev Res (Phila) (2015) 0.80
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. World J Urol (2016) 0.79
Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway. Arab J Urol (2012) 0.79
Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration. Front Oncol (2013) 0.79
Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma. PLoS One (2015) 0.79
Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases. Virchows Arch (2013) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol (2015) 0.79
Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue. Oncol Lett (2015) 0.79
Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors. Am J Pathol (2009) 0.78
Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation. J Am Soc Nephrol (2015) 0.78
Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions. J Radiat Res (2015) 0.76
Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma. Am J Cancer Res (2013) 0.76
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest (2016) 0.76
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. Am J Cancer Res (2014) 0.76
Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. Onco Targets Ther (2012) 0.75
miR-137 inhibits renal cell carcinoma growth in vitro and in vivo. Oncol Lett (2016) 0.75
Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro. Onco Targets Ther (2017) 0.75
Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. Int J Clin Exp Pathol (2015) 0.75
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res (2013) 0.75
Targeting of Tumor Growth and Angiogenesis Underlies the Enhanced Antitumor Activity of Lenvatinib in Combination with Everolimus. Cancer Sci (2017) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther (2016) 0.75
Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis. PLoS One (2017) 0.75
Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma. World J Urol (2011) 0.75
Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma. Int J Clin Oncol (2014) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem (2007) 4.79
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
GeneWays: a system for extracting, analyzing, visualizing, and integrating molecular pathway data. J Biomed Inform (2004) 4.57
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Realist randomised controlled trials: a new approach to evaluating complex public health interventions. Soc Sci Med (2012) 4.44
Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A (2007) 4.20
Frontiers of biomedical text mining: current progress. Brief Bioinform (2007) 4.11
Validity of self-reported height and weight and predictors of bias in adolescents. J Adolesc Health (2005) 4.09
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial. BMJ (2012) 3.44
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 3.38
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol (2002) 3.14
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Flexible ureteroscopy and laser lithotripsy for multiple unilateral intrarenal stones. Eur Urol (2008) 2.97
Hid, Rpr and Grim negatively regulate DIAP1 levels through distinct mechanisms. Nat Cell Biol (2002) 2.95
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol (2002) 2.50
Improving the reporting of public health intervention research: advancing TREND and CONSORT. J Public Health (Oxf) (2008) 2.49
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol (2012) 2.44
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol (2009) 2.43
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Questionnaire survey of users of NHS walk-in centres: observational study. Br J Gen Pract (2002) 2.38
Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol (2009) 2.37
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Global levels of histone modifications predict prognosis in different cancers. Am J Pathol (2009) 2.28
Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park) (2012) 2.25
Training practitioners to deliver opportunistic multiple behaviour change counselling in primary care: a cluster randomised trial. BMJ (2013) 2.22
An observational study comparing quality of care in walk-in centres with general practice and NHS Direct using standardised patients. BMJ (2002) 2.22
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol (2009) 2.05
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A (2002) 2.00
Color Doppler sonography reliably identifies testicular torsion in boys. Urology (2009) 1.95
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
Mouse model for human arginase deficiency. Mol Cell Biol (2002) 1.88
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A (2005) 1.84
Impact of NHS walk-in centres on the workload of other local healthcare providers: time series analysis. BMJ (2003) 1.81
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion (2010) 1.80
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 1.80
Flexible ureteroscopy and laser lithotripsy for single intrarenal stones 2 cm or greater--is this the new frontier? J Urol (2008) 1.80
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Automatically classifying sentences in full-text biomedical articles into Introduction, Methods, Results and Discussion. Bioinformatics (2009) 1.74
Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol (2009) 1.73
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69
Process evaluation in complex public health intervention studies: the need for guidance. J Epidemiol Community Health (2013) 1.68
Exploratory randomised controlled trial of a mindfulness-based weight loss intervention for women. Appetite (2008) 1.68
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Arginases I and II: do their functions overlap? Mol Genet Metab (2004) 1.67
What is the role of walk-in centres in the NHS? BMJ (2002) 1.65